Dacomitinib vs Erlotinib for the treatment of advanced Non-Small Cell Lung Cancer (#436)
Laufzeit: 01.01.2012 - 31.12.2017
imported
Kurzfassung
A randomized, double blind, phase III efficacy and safety study of PF00299804 (Dacomitinib) versus Erlotinib for the treatment of advanced non-small cell lung cancer following progression after, or intolerance to, at least one prior chemotherapy (ARCHER1009)
